

# The age-related macular degeneration market is poised for steady growth fueled by demographic trends


PORTLAND, OR, UNITED STATES,  
February 4, 2025 /EINPresswire.com/ --

The [age-related macular degeneration \(AMD\) market](#) is experiencing

significant growth, driven by an aging global population and advancements in treatment options. Valued at approximately \$9.4 billion in 2022, the market is projected to reach \$15.4 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5% from 2023 to 2032. This article explores the key aspects of the AMD market,

including its types, treatment options, market trends, and competitive landscape.

including its types, treatment options, market trends, and competitive landscape.



**AGE RELATED MACULAR DEGENERATION (AMD) MARKET**  
OPPORTUNITIES AND FORECAST, 2023-2032

Age related macular degeneration (amd) market is expected to reach **\$15.4 Billion** in 2032

Growing at a **CAGR of 5%** (2023-2032)

Report Code: A03198, www.alliedmarketresearch.com

age-related macular degeneration market -----

Get a Sample Copy of this Report: <https://www.alliedmarketresearch.com/request-sample/3538>

## Overview of Age-Related Macular Degeneration

- Definition: AMD is a progressive eye disease affecting the macula, leading to central vision loss.
- Types:
- Dry AMD: More prevalent; characterized by yellow deposits in the macula.
- Wet AMD: Less common; involves abnormal blood vessel growth beneath the macula.

## Treatment Options

- Dry AMD:
- Vitamin supplements and lifestyle changes.
- Wet AMD:
- Anti-VEGF therapy (e.g., aflibercept, ranibizumab) administered via injections to inhibit abnormal blood vessel growth.

## Market Trends and Forecast

- Growth Drivers:

- Increasing prevalence of AMD among the elderly.
- Rise in adoption of AMD drugs.
- Development of new treatment options.
- Future Projections:
- By 2050, the global population aged 60 and older is expected to reach 2.1 billion, amplifying the demand for AMD treatments.

### Segmental Analysis

- By Drug Type:
- Aflibercept and ranibizumab are leading segments due to their effectiveness in treating wet AMD.
- By Disease Type:
- Wet AMD is currently dominating the market due to its severe impact on vision.
- By Distribution Channel:
- Hospital pharmacies are the primary distribution channel, driven by prescription sales.
- By Region:
- North America holds a significant market share, attributed to advanced healthcare systems and high awareness levels regarding AMD.

### Competitive Landscape

Several pharmaceutical companies are actively involved in addressing the unmet needs within the AMD market. Key players include:

- Regeneron Pharmaceuticals Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Biogen
- Bayer AG

### Recent Product Approvals

1. Beovu (brolucizumab): Approved for wet AMD treatment by the European Commission in February 2020.
2. Byooviz (ranibizumab-nuna): FDA-approved for neovascular wet AMD in September 2021.
3. SYFOVRE (pegcetacoplan): FDA-approved for geographic atrophy secondary to AMD in February 2023.

### Challenges Facing the Market

Despite its growth potential, the AMD market faces challenges such as:

- High Treatment Costs: The average cost per patient for AMD treatment is approximately \$5,198.65, which may limit access for some patients.
- Insurance Coverage Issues: Insufficient coverage in developing regions can hinder market expansion.

### Conclusion

The age-related macular degeneration market is poised for steady growth fueled by demographic trends and advancements in treatment options. As the global population ages, addressing the challenges associated with AMD will be crucial for improving patient outcomes and expanding market opportunities. The ongoing development of innovative therapies and increasing awareness will play significant roles in shaping this vital sector of healthcare.

Enquire Before Buying: <https://www.alliedmarketresearch.com/purchase-enquiry/3538>

David Correa

Allied Market Research

+ + 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/782913607>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.